Bring Them On: 40 Orphan, Cancer Drugs Set For Priority Review In China
Executive Summary
New treatments for spinal muscular atrophy, glioblastoma, Gaucher's disease and others could be soon be hitting the China market following the awarding of priority reviews to a large list of novel therapies.
You may also be interested in...
China Calling: Dozens Of Drug Firms Handpicked For Fast Track Reviews
Four dozen innovative new drugs are slated to be reviewed under China's fast-track system, including more than 20 products for rare diseases.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.